Benzinga''s Top Ratings Upgrades, Downgrades For June 1, 2022
Upgrades Citigroup upgraded the previous rating for FinVolution Group (NYSE: FINV ) from Neutral to Buy. FinVolution Gr earned $0.30 in the first quarter, compared to $0.31 in the year-ago quarter. The stock has a 52-week-high of $10.41 and a 52-week-low of $2.68. At the end of the last trading period, FinVolution Gr closed at $4.21. For Noble Corp (NYSE: NE ), BTIG upgraded the previous rating of Neutral to Buy. At the moment, the stock has a 52-week-high of $37.77 and a 52-week-low of $20.34. Noble closed at $36.28 at the end of the last trading period. For Vertex Pharmaceuticals Inc (NASDAQ: VRTX ), Maxim Group upgraded the previous rating of Hold to Buy. For the first quarter, Vertex Pharmaceuticals had an EPS of $3.52, compared to year-ago quarter EPS of $2.98. The stock has a 52-week-high of $292.75 and a 52-week-low of $176.36. At the end of the last trading period, Vertex Pharmaceuticals closed at $268.65. For Visteon Corp (NASDAQ: VC ), Morgan Stanley upgraded the previous rating of Underweight to Equal-Weight.
Benzinga''s Top Ratings Upgrades, Downgrades For June 1, 2022
Upgrades Citigroup upgraded the previous rating for FinVolution Group (NYSE: FINV ) from Neutral to Buy. FinVolution Gr earned $0.30 in the first quarter, compared to $0.31 in the year-ago quarter. The stock has a 52-week-high of $10.41 and a 52-week-low of $2.68. At the end of the last trading period, FinVolution Gr closed at $4.21. For Noble Corp (NYSE: NE ), BTIG upgraded the previous rating of Neutral to Buy. At the moment, the stock has a 52-week-high of $37.77 and a 52-week-low of $20.34. Noble closed at $36.28 at the end of the last trading period. For Vertex Pharmaceuticals Inc (NASDAQ: VRTX ), Maxim Group upgraded the previous rating of Hold to Buy. For the first quarter, Vertex Pharmaceuticals had an EPS of $3.52, compared to year-ago quarter EPS of $2.98. The stock has a 52-week-high of $292.75 and a 52-week-low of $176.36. At the end of the last trading period, Vertex Pharmaceuticals closed at $268.65. For Visteon Corp (NASDAQ: VC ), Morgan Stanley upgraded the previous rating of Underweight to Equal-Weight.